From discovery to IND: Roadmap to a successful antibacterial project

Speakers:

  • Patricia Bradford, Antimicrobial Development Specialists LLC (US)
  • Alita Miller, Entasis Therapeutics (US)

Moderator: Michael Mourez, École d’Ingénieurs de PURPAN (France)

Presentations:

Screen to pre-clinical candidate (Alita Miller):

  • Discovery strategies
  • Hit-to-lead generation
  • MOA studies
  • Spectrum of activity
  • Resistance studies
  • In vitro toxicity assessments
  • PK/PD characterization

Pre-clinical candidate to phase 1 (Patricia Bradford):

  • Non-clinical package requirements for first-in-human studies
  • Dose selection
  • Non-clinical toxicity
  • CMC considerations
  • Regulatory process/pathways

The presentations were followed by a Q&A session.

This live webinar including interactive Q&A session was broadcast on 25 February 2021.

If you have questions or comments, please let us know: revive@gardp.org.

Download the speakers’ slides here
2021-03-09T13:26:46+00:00

REVIVE

REVIVE is a space for everybody with an interest in antimicrobial R&D.

The Global Antibiotic Research and Development Partnership (GARDP) is a not-for-profit organization developing new treatments for drug-resistant infections that pose the greatest threat to health. We were created to ensure that everyone who needs antibiotics receives effective and affordable treatment, no matter where they live. We aim to develop five new treatments by 2025 to fight drug-resistant infections, focusing on sexually transmitted infections, sepsis in newborns and infections in hospitalized adults and children.

CONNECT